Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering. Under the new ownership structure, CEO Luca Borella retained his position and a significant minority stake. Ardian intends to leverage its global network and "Buy-and-Build" expertise to accelerate Masco's footprint in North America and Asia, while deepening its technological capabilities in the high-growth biologics and injectable drug sectors.

The transaction values MASCO GROUP at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.